These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 35360663)

  • 41. Ceftaroline fosamil versus ceftriaxone for the treatment of community-acquired pneumonia: individual patient data meta-analysis of randomized controlled trials.
    Taboada M; Melnick D; Iaconis JP; Sun F; Zhong NS; File TM; Llorens L; Friedland HD; Wilson D
    J Antimicrob Chemother; 2016 Apr; 71(4):862-70. PubMed ID: 26702925
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Summary of ceftaroline fosamil clinical trial studies and clinical safety.
    File TM; Wilcox MH; Stein GE
    Clin Infect Dis; 2012 Sep; 55 Suppl 3():S173-80. PubMed ID: 22903949
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ceftaroline fosamil for treating skin and skin structure infections or community-acquired pneumonia in patients with renal insufficiency.
    Maggiore C; Pasquale T; Cole P; Friedland HD
    Expert Rev Clin Pharmacol; 2015 Jan; 8(1):141-53. PubMed ID: 25467425
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A novel treatment option for MRSA pneumonia: ceftaroline fosamil-yielding new hope in the fight against a persistent infection.
    Arshad S; Hartman P; Zervos MJ
    Expert Rev Anti Infect Ther; 2014 Jul; 12(7):727-9. PubMed ID: 24898885
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ceftaroline fosamil for the treatment of community-acquired bacterial pneumonia in elderly patients.
    Udeani G; Evans J; Cole P; Friedland HD
    Hosp Pract (1995); 2014 Aug; 42(3):109-15. PubMed ID: 25255412
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ceftaroline fosamil for the treatment of acute bacterial skin and skin structure infections in obese patients.
    Evans JD; Udeani G; Cole P; Friedland HD
    Postgrad Med; 2014 Sep; 126(5):128-34. PubMed ID: 25295657
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Baseline Characteristics and Outcomes Among Patients with Complicated Skin and Soft Tissue Infections Admitted to the Intensive Care Unit: Analysis of the Phase 3 COVERS Randomized Trial of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam.
    Sánchez-García M; Hammond J; Yan JL; Kantecki M; Ansari W; Dryden M
    Infect Dis Ther; 2020 Sep; 9(3):609-623. PubMed ID: 32607967
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ceftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-Gram-positive activity.
    Biek D; Critchley IA; Riccobene TA; Thye DA
    J Antimicrob Chemother; 2010 Nov; 65 Suppl 4():iv9-16. PubMed ID: 21115457
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A series of pharmacokinetic studies of ceftaroline fosamil in select populations: normal subjects, healthy elderly subjects, and subjects with renal impairment or end-stage renal disease requiring hemodialysis.
    Riccobene T; Jakate A; Rank D
    J Clin Pharmacol; 2014 Jul; 54(7):742-52. PubMed ID: 24431097
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Off-label use of ceftaroline fosamil: A systematic review.
    Pani A; Colombo F; Agnelli F; Frantellizzi V; Baratta F; Pastori D; Scaglione F
    Int J Antimicrob Agents; 2019 Nov; 54(5):562-571. PubMed ID: 31279152
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In vivo efficacy of ceftaroline fosamil in a methicillin-resistant panton-valentine leukocidin-producing Staphylococcus aureus rabbit pneumonia model.
    Croisier-Bertin D; Hayez D; Da Silva S; Labrousse D; Biek D; Badiou C; Dumitrescu O; Guerard P; Charles PE; Piroth L; Lina G; Vandenesch F; Chavanet P
    Antimicrob Agents Chemother; 2014; 58(4):1855-61. PubMed ID: 24395236
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Ceftaroline fosamil in community-acquired and nosocomial pneumonia].
    Calbo E; Zaragoza R
    Enferm Infecc Microbiol Clin; 2014 Mar; 32 Suppl 2():38-43. PubMed ID: 24702978
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Randomized, placebo-controlled study to assess the impact on QT/QTc interval of supratherapeutic doses of ceftazidime-avibactam or ceftaroline fosamil-avibactam.
    Das S; Armstrong J; Mathews D; Li J; Edeki T
    J Clin Pharmacol; 2014 Mar; 54(3):331-40. PubMed ID: 24150927
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ceftaroline fosamil as first-line versus second-line treatment for acute bacterial skin and skin structure infections (ABSSSI) or community-acquired bacterial pneumonia (CABP).
    Guervil DJ; Kaye KS; Hassoun A; Cole P; Huang XY; Friedland HD
    J Chemother; 2016 Jun; 28(3):180-6. PubMed ID: 25817579
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phase 2 Study of the Safety, Pharmacokinetics and Efficacy of Ceftaroline Fosamil in Neonates and Very Young Infants With Late-onset Sepsis.
    Bradley JS; Stone GG; Chan PLS; Raber SR; Riccobene T; Mas Casullo V; Yan JL; Hendrick VM; Hammond J; Leister-Tebbe HK
    Pediatr Infect Dis J; 2020 May; 39(5):411-418. PubMed ID: 32091493
    [TBL] [Abstract][Full Text] [Related]  

  • 56. In-use Stability of Ceftaroline Fosamil in Elastomeric Home Infusion Systems and MINI-BAG Plus Containers.
    Bhattacharya S; Parekh S; Dedhiya M
    Int J Pharm Compd; 2015; 19(5):432-6. PubMed ID: 26775451
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Insights into the l,d-Transpeptidases and d,d-Carboxypeptidase of Mycobacterium abscessus: Ceftaroline, Imipenem, and Novel Diazabicyclooctane Inhibitors.
    Dousa KM; Kurz SG; Taracila MA; Bonfield T; Bethel CR; Barnes MD; Selvaraju S; Abdelhamed AM; Kreiswirth BN; Boom WH; Kasperbauer SH; Daley CL; Bonomo RA
    Antimicrob Agents Chemother; 2020 Jul; 64(8):. PubMed ID: 32393499
    [No Abstract]   [Full Text] [Related]  

  • 58. Ceftaroline fosamil: a brief clinical review.
    Shirley DA; Heil EL; Johnson JK
    Infect Dis Ther; 2013 Dec; 2(2):95-110. PubMed ID: 25134474
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ceftaroline fosamil treatment outcomes compared with standard of care among hospitalized patients with complicated skin and soft tissue infections.
    Karve S; Hackett J; Levinson J; Gibson E; Battersby A
    J Comp Eff Res; 2016 Jul; 5(4):393-405. PubMed ID: 26946948
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ceftaroline Fosamil Use in 2 Pediatric Patients With Invasive Methicillin-Resistant Staphylococcus aureus Infections.
    Williams AW; Newman PM; Ocheltree S; Beaty R; Hassoun A
    J Pediatr Pharmacol Ther; 2015; 20(6):476-80. PubMed ID: 26766937
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.